GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Price-to-Owner-Earnings

Biocon (NSE:BIOCON) Price-to-Owner-Earnings : 14.70 (As of May. 31, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Price-to-Owner-Earnings?

As of today (2025-05-31), Biocon's share price is ₹335.85. Biocon's Owner Earnings per Share (TTM) ended in Mar. 2025 was ₹22.84. It's Price-to-Owner-Earnings for today is 14.70.


The historical rank and industry rank for Biocon's Price-to-Owner-Earnings or its related term are showing as below:

NSE:BIOCON' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 13.66   Med: 47.54   Max: 193.53
Current: 14.48

During the past 13 years, the highest Price-to-Owner-Earnings of Biocon was 193.53. The lowest was 13.66. And the median was 47.54.


NSE:BIOCON's Price-to-Owner-Earnings is ranked better than
74.72% of 178 companies
in the Biotechnology industry
Industry Median: 28.765 vs NSE:BIOCON: 14.48

As of today (2025-05-31), Biocon's share price is ₹335.85. Biocon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was ₹8.46. Therefore, Biocon's PE Ratio (TTM) for today is 39.70.

As of today (2025-05-31), Biocon's share price is ₹335.85. Biocon's EPS without NRI for the trailing twelve months (TTM) ended in was ₹1.20. Therefore, Biocon's PE Ratio without NRI for today is 279.64.

During the past 13 years, Biocon's highest PE Ratio without NRI was 282.68. The lowest was 20.17. And the median was 51.62.


Biocon Price-to-Owner-Earnings Historical Data

The historical data trend for Biocon's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Price-to-Owner-Earnings Chart

Biocon Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.04 172.10 50.83 32.85 14.94

Biocon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.85 - - - 14.94

Competitive Comparison of Biocon's Price-to-Owner-Earnings

For the Biotechnology subindustry, Biocon's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocon's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocon's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Biocon's Price-to-Owner-Earnings falls into.


;
;

Biocon Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Biocon's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=335.85/22.84
=14.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocon  (NSE:BIOCON) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Biocon Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Biocon's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon Business Description

Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.

Biocon Headlines

No Headlines